CRL · Charles River Laboratories International Inc
Price
Snapshot
50 fields · last close| Market Cap | $14.33B |
| P/E | — |
| Float | 47.92M |
| Beta | 1.37 |
| Volatility | 34.4% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 70.8 |
| Price | 300.11 |
| Change | −0.01% |
| Prev Close | 300.15 |
| Open | 306.09 |
| Day Low | 296.35 |
| Day High | 308.83 |
| Avg Vol | 1 |
| Avg $ Vol | $305.2M |
| 52W High | 333.30 |
| 52W Low | 146.20 |
| 52W Pos | 82.3% |
| From High | −9.96% |
| From Low | +105.27% |
| Max DD 1Y | −33.88% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.45% |
| SMA 50 | +3.89% |
| SMA 200 | +39.62% |
| RSI (14) | 55.6 |
| Vol 30D | 36.5% |
| Vol 90D | 40.3% |
| 1Y Range | 146–333 |
| Daily bars | 537 |
| Perf Week | −0.54% |
| Perf Month | +6.56% |
| Perf Quarter | +36.62% |
| Perf Half Y | +61.77% |
| Perf Year | +71.56% |
| Perf YTD | +48.26% |
| Prev Day | −0.01% |
| Clavix | B- |
| Debt / Eq | 0.51 |
| Curr Ratio | 1.29 |
| Int Cover | -0.4× |
| FCF Margin | 18.4% |
| Rev Growth | −0.8% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 12 / 19 |
What CRL does
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.
The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services.
The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services.
The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization.
Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development.
Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Clavix risk grade
regraded every trading dayCRL grades B-, 70.8 of 100. Steadiest on News Sentiment (64), most exposed on Price Stability (56, mixed). 0 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 12 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| CRL | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.37 | 1.18 |
| Volatilityannualized | 34.4% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −33.9% | — |
| Typical daily movemedian absolute daily change | 1.48% | — |
| Days beyond ±3%of the last 252 sessions | 53 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CRL | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.37 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CRL | |
|---|---|
| 1 week | −0.5% |
| 1 month | +6.6% |
| Year to date | +48.3% |
| 1 year | +71.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CRL | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 8 Sep |
| Average score0 most bearish, 100 most bullish | 70 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 1 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| CRL | |
|---|---|
| Revenue growthyear over year | −0.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openCTIBIOTECH signed a strategic partnership with Beijing Vital River, identified as a Charles River Laboratories company, to commercialize human tissue bioassays and New Approach Methodologies in China.
CTIBIOTECH announced a strategic partnership and memorandum of understanding with Beijing Vital River, a Charles River Laboratories company, to bring human bioassay technology to China and accelerate preclinical biomedical and cosmetics research and development.
Charles River Laboratories has partnered with Australian biotech Magellan Stem Cells to help develop and advance Magellan's regenerative medicine candidate, Zelestrocel, through clinical stages. The article provides no further details on the financial terms or timeline.
Charles River Laboratories announced a collaboration with Magellan Stem Cells, a private Australian biotech, to support the development and clinical advancement of Magellan's proprietary stem cell-based therapies and regenerative medicine products, using Charles River's biologics quality control and cGMP (current Good Manufacturing Practice - the regulatory standard for safe production of biologic medicines) expertise.
Charles River Laboratories announced a collaboration with Magellan Stem Cells, a private Australian biotech, to support the development and clinical advancement of Magellan's proprietary stem cell-based therapies and regenerative medicine products using Charles River's biologics quality control and cGMP (current Good Manufacturing Practice, the regulatory standard for producing clinical-grade medicines) viral and recombinant manufacturing capabilities.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RVTY | Revvity Inc | B | $17.03B | 71.70 | 1.09 | Compare |
| MEDP | Medpace Holdings Inc | B | $17.26B | 35.12 | 1.11 | Compare |
| TEM | Tempus AI Inc | D- | $11.68B | — | 2.37 | Compare |
| TECH | Bio-Techne Corp | B | $11.38B | 62.58 | 1.28 | Compare |
| RGEN | Repligen Corp | B- | $11.14B | 268.12 | 1.14 | Compare |
| AVTR | Avantor Inc | B- | $11.11B | — | 0.97 | Compare |
| QGEN | Qiagen NV | B+ | $9.51B | 23.22 | 0.59 | Compare |
| TXG | 10X Genomics Inc | C- | $9.10B | — | 2.02 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.